In last trading session, Editas Medicine Inc (NASDAQ:EDIT) saw 1.96 million shares changing hands with its beta currently measuring 2.22. Company’s recent per share price level of $1.12 trading at -$0.06 or -5.08% at ring of the bell on the day assigns it a market valuation of $92.93M. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.82 million shares which gives us an average trading volume of 3.82 million if we extend that period to 3-months.

For Editas Medicine Inc (EDIT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.58 in the current quarter.

Editas Medicine Inc (NASDAQ:EDIT) trade information

Upright in the red during last session for losing -5.08%, in the last five days EDIT remained trading in the red while hitting it’s week-highest on Friday, 03/28/25 when the stock touched $1.12 price level, adding 14.54% to its value on the day. Editas Medicine Inc’s shares saw a change of -11.81% in year-to-date performance and have moved -13.85% in past 5-day. Editas Medicine Inc (NASDAQ:EDIT) showed a performance of -45.37% in past 30-days. Number of shares sold short was 13.15 million shares which calculate 1.74 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 87.56% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -346.43% in reaching the projected high whereas dropping to the targeted low would mean a loss of -346.43% for stock’s current value.

Editas Medicine Inc (EDIT) estimates and forecasts

This year revenue growth is estimated to fall -66.47% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 786.1k for the same. And 10 analysts are in estimates of company making revenue of 1.29M in the next quarter. Company posted 1.14M and 513k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.48% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 49.07% while estimates for its earnings growth in next 5 years are of 23.95%.

Editas Medicine Inc (NASDAQ:EDIT)’s Major holders

Insiders are in possession of 0.32% of company’s total shares while institution are holding 65.85 percent of that, with stock having share float percentage of 66.06%. Investors also watch the number of corporate investors in a company very closely, which is 65.85% institutions for Editas Medicine Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at EDIT for having 8.03 million shares of worth $37.51 million. And as of 2024-06-30, it was holding 9.8032 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 7.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4551 of outstanding shares, having a total worth of $36.34 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.59 shares of worth $2.9 million or 3.12% of the total outstanding shares. The later fund manager was in possession of 2.15 shares on Feb 28, 2025 , making its stake of worth around $2.4 million in the company or a holder of 2.59% of company’s stock.